This article is more than 5 years old. Information may no longer be current.

PVR treatment enters phase 2 trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — An investigational drug for the treatment of proliferative vitreoretinopathy has moved into phase 2 trials, the developer said. VitrenASE, a ribozyme-based drug that targets the proliferating cell nuclear antigen gene, is being investigated at more than 10 sites in the United States, with 150 patients enrolled in its PVR trial.

The drug is expected to reduce the incidence of redetachment in patients who have undergone retinal detachment surgery. To date, there are no approved pharmaceutical treatments for PVR, according to a press release from Immusol, the drug's developer.

VitrenASE is also in development as a treatment for proliferative diabetic retinopathy and to prevent proliferation and scarring around the filter after glaucoma surgery.